Skip to main content
. 2016 Nov 16;7(52):86313–86325. doi: 10.18632/oncotarget.13388

Figure 1. Osimertinib blocks glycolysis in sensitive but not resistant cells.

Figure 1

(A) Cells were plated and treated with either vehicle control, 300 nM gefinitib (Gef) or 160 nM osimertinib (Osi) for 24 h. Conditioned media was analysed for lactate concentration, values shown are means relative to vehicle control +/− SEM (*p < 0.05; n = 3). (B) Cells treated as in (A), lysed and subjected to Western blotting. (C) Cells were treated with 160 nM osimertinib or vehicle control for 24h, and conditioned media was analysed for lactate concentration. Values shown are means relative to vehicle control +/− SEM (*p < 0.05; n ≥ 3). (D) Cells were treated as in (C), lysed and subjected to Western blotting. (E) Cells were treated with 160 nM osimertinib or vehicle control for 24 h, and conditioned media was analysed as in (A) (n = 3). (F) Cells were treated as in (E), lysed and subjected to Western blotting. (G) Cells were treated with 160 nM osimertinib or vehicle control for 24 h, cells were lysed and subjected to an enzymatic hexokinase assay. Results were normalized to total protein level and values shown are means relative to vehicle control (*p < 0.05; n = 3). (H) PC9 cells were treated with 160 nM osimertinib or vehicle control for 24 h, RNA was isolated and relative levels of mRNA expression was determined by qPCR. Values shown are means relative to vehicle control +/− SEM (n = 3). All osimertinib-treated samples showed significant differences from DMSO control (p < 0.05).